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Abstract 
 
 
There is a renewed interest in better conceptualizing trajectories of attention- 
deficit/hyperactivity disorder (ADHD) from childhood to adulthood, driven by 
an increased recognition of long-term impairment and potential persistence 
beyond childhood and adolescence. This review addresses the following major 
issues relevant to the course of ADHD in light of current evidence from 
longitudinal studies: (1) conceptual and methodological issues related to 
measurement of persistence of ADHD, (2) estimates of persistence rate from 
childhood to adulthood and its predictors, (3) long-term negative outcomes of 
childhood ADHD and their early predictors, and (4) the recently proposed new 
adult-onset ADHD. Estimates of persistence vary widely in the literature, and 
diagnostic criteria, sample characteristics, and information source are the most 
important factors explaining variability among studies. Evidence indicates that 
ADHD  severity,  comorbid  conduct  disorder  and  major  depressive  disorder, 
and treatment for ADHD are the main predictors of ADHD persistence from 
childhood  to adulthood.  Comorbid  conduct  disorder  and  ADHD  severity  in 
childhood are the most important predictors of adverse outcomes in adulthood 
among  children  with ADHD.  Three  recent  population  studies  suggested  the 
existence of a significant proportion of individuals who report onset of ADHD 
symptoms and impairments after childhood. Finally, we highlight areas for 
improvement to increase our understanding of ADHD across the life span.
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This article is part of the Topical Collection on Attention-Deficit Disorder 
 
 
 
Introduction 
 
Attention-deficit/hyperactivity  disorder (ADHD) is a neurobiological disorder 
characterized by a persistent and impairing pattern of inattentive, hyperactive, 
and/or impulsive symptoms [ 1 ]. Meta-analyses suggest prevalence rates around 
5 to 7.1 % in childhood and 2.5 to 5 % in adulthood [ 2, 3, 4 ]. The disorder is 
associated with adverse outcomes for affected individuals, their families, and 
society in general [ 5 ]. 
 
 
There is recent interest in better conceptualized adult ADHD [ 6 ] and its 
trajectories from childhood to adulthood [ 5 ]. A previous meta-analysis found 
that only 15 % of diagnosed children continued presenting full ADHD diagnosis 
in adulthood, although 65 % presented with a subsyndromal phenotype [ 7 ]. This 
figure would suggest a much lower adult ADHD prevalence rate (15 % of 5–7 %  
= 0.8–1.1 %) than what has been detected both in meta-analyses (2.5–5 %) 
[ 3, 4 ] and in a multinational study on ADHD prevalence in adults (3.4 %) [ 8 ]. 
There is a current debate about reasons for this discrepancy. Some investigators 
suggest that the 15 % persistence rate is a clear underestimation due to change of 
informants between adult and child assessments and inadequacy of the ADHD 
diagnostic criteria for adults. Major aspects of both the ADHD phenotype and its 
impairments might be different in adults, and other approaches to define 
persistence, like cognitive and social dysfunction, are lacking in the literature [ 6 
]. In addition, controversies also exist surrounding new findings suggesting an 
unexpected ADHD trajectory. Three recent population studies found a 
substantial number of individuals with onset of clinically significant ADHD 
symptoms and impairments after childhood, challenging the established notion 
of ADHD as exclusively a childhood-onset neurodevelopmental disorder [ 9 •, 
10 •, 11 •]. 
 
 
This narrative review of the literature addresses the following topics that might 
increase our understanding about these discrepant findings: (a) conceptual and
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methodological issues inherent to the study of ADHD trajectories, (b) data on 
persistence rates from longitudinal ADHD studies, (c) predictors of ADHD 
persistence from childhood to adulthood, (d) child and adolescent predictors of 
adult ADHD negative outcome, and (e) new adult-onset cases and their 
predictors. 
 
 
Conceptual and Methodological Issues Inherent to 
the Study of ADHD Trajectories 
 
 
(a) ADHD diagnosis 
 
 
In the last 50 years, the diagnostic criteria for ADHD from Diagnostic and 
Statistical Manual of Mental Disorders second edition (DSM-II) to DSM-5 
have  been modified [ 1, 12, 13 ]  Please include citation: 
American Psychiatric Association. (1968). Diagnostic and statistical manual of mental 
disorders (2nd ed.). Washington, DC: American Psychiatric Association.   . Previous 
work has demonstrated that the use of different diagnostic criteria is one of 
the major factors influencing variability in ADHD prevalence rates 
worldwide over the last three decades [ 2, 14 ]. ADHD persistence is the 
proportion affected by the diagnostic definitions in childhood 
(denominator) who also meet the definition in adult life (numerator) 
[ 6 9 •].   There should be a comma separating 6 and 9.   A birth cohort study 
with assessments of the disorder from childhood to adulthood (15) 
provided different ADHD persistence rates depending on the diagnostic 
system used on multiple follow-up waves [ 15 ]. An adult norm-based 
diagnostic approach yielded the highest persistence rate compared to any 
other approaches (29.3 % against 11.2 to 13.8 % for strict criteria 
definitions). While some studies assessed individuals at baseline in 
childhood for ADHD by using previous classifications (DSM-II, DSM-III) 
[ 16, 17, 18, 19, 20, 21 ], others used more contemporary systems such as 
DSM-IV [ 11, •, 22, 23 ]. Assessments at follow-up are likewise a source of 
heterogeneity in persistence estimates: Studies have used DSM-III 
[ 17, 24 ], DSM-IV [ 15, 20, 21, 25 ], and DSM-5 [ 9 •, 11 •] criteria to 
determine ADHD diagnosis in adulthood. Differences of criteria may 
occur even in a same study in longitudinal assessments. 
AQ2 
 
 
One study evaluated how differences in case definition might impact 
persistence estimates in the 16-year clinical follow-up of the Multimodal 
Treatment Study of ADHD (MTA) [ 26, •]. Persistence estimates varied 
widely from 1.9 % (requiring DSM-IV criteria, combining parent and self- 
report in the Diagnostic Interview Schedule for Children (DISC) with an
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item-level AND rule) to 61.4 % (requiring norm-based symptom count, 
combining parent and self-report in the DISC with an item-level OR rule). 
Based on findings from a Receiver Operating Curve (ROC)ROC) analysis 
of impairment, the authors concluded that the best combination of 
sensitivity and specificity was achieved by using a norm-based threshold 
of four symptoms from either list (more than two standard deviations 
above the mean of the local normative comparison group) assessed with 
rating scales and combining parental and self-report information with an 
item-level OR rule. This approach yielded a persistence rate of 60 % for 
symptoms and 41 % for symptoms with impairment. 
 
 
Although the presence of impairment has been required by the successive 
revisions of diagnostic criteria for ADHD, the level of impairment 
required is not unanimous. The level of impairment substantially affects 
variability in ADHD prevalence rates worldwide and across the last three 
decades [ 2, 14 ]. Using full DSM-5 criteria, a recent population study 
assessing ADHD prevalence in adults [ 27 ] found a rate of 3.55 % (95 % 
CI 2.98–4.12 %) for at least moderate impairment, but only 1.4 % for 
severe clinical impairment. Thus, diagnostic rates vary substantially from 
one study to another depending on the level of impairment required for 
diagnosing the disorder at baseline and endpoint [ 28 ]. 
 
 
Another conceptual issue is the source of impairment, which has varied 
across studies. Some studies used general measures of impairment, such as 
the Clinical Global Assessment Scale [ 29 ], Clinical Global Impression 
Scale [ 30 ], or the Global Assessment of Functioning [ 31 ], while others 
used measures that specifically assess impairment derived from ADHD 
symptoms, such as questions included in ADHD modules of structured or 
semi-structured diagnostic instruments [ 11, •, 20, 21 ]. Instruments created 
to assess impairment specifically related to ADHD, as the Barkley 
Functional Impairment Scale (BFIS)were was also used [ 22 ]. Two 
paramount clinical follow-ups, the multimodal treatment study of children 
with ADHD (MTA) [ 26, •] and the Pittsburgh ADHD Longitudinal Study 
(PALS) [ 32 ], used the Impairment Rating Scale (IRS) proposed by 
Fabiano et al. for children with ADHD [ 33 ]. Although it is questionable 
whether the source of impairment can be clearly specified when 
comorbidity is the rule, persistence rates ascertained by different 
instruments, even for the same level of impairment, may be substantially 
different. 
 
 
(b) Sample characteristics
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The origin of the sample (community or clinical) affects prevalence rates 
and clinical correlates of psychiatric disorders [ 34 ]. Clinical samples of 
individuals with ADHD in general include more severe cases than 
population samples and thus report increased comorbidity [ 35 ]. Part of 
this increased morbidity is expected according to the “Berkson’s bias,” a 
mathematical bias due to restricting the sample to those individuals 
seeking clinical treatment and showing greater levels of severity and 
comorbidity [ 34, 36 ]. Thus, it is not surprising that ADHD persistence 
rates appear to be higher in clinical samples [ 18, 22, 23, 28 ] than in 
population-based samples [ 9 •, 10 •, 11 •]. Barriers to health services 
across countries also affect persistence rates. It is expected that clinical 
samples will select more severe and socially deprived cases in countries 
with accessible health care like the UK or Scandinavian countries [ 37 ]. 
 
 
Additionally, retention rate is related to selection bias [ 38 ] affecting the 
representativeness of the sample, especially in population-based samples. 
A population-based sample with a substantial amount of participants lost 
to follow-up might underestimate persistence rates, since severe cases may 
have a higher risk of persistence and a higher risk of not attending several 
longitudinal assessments [ 39 ]. 
 
 
(c) Demographic aspects 
 
 
Longitudinal ADHD studies assess individuals at different ages both at 
baseline in childhood and endpoint during adulthood [ 11, •, 40 ]. 
Considering the general trend that prevalence rates of ADHD decrease 
across the life cycle, regardless of the criteria used (see Faraone et al. [ 7 
]), age at assessment might be another factor influencing persistence 
rates. The literature shows that ADHD prevalence in adolescence is about 
half of that in childhood [ 2 ] and prevalence estimates continue to 
decrease in adulthood. This has been illustrated most clearly by a long 
ADHD follow-up study that assessed participants with childhood-onset 
ADHD at different time points in adulthood. The prevalence of ADHD 
declined to 43 % at 18 years of age and 22 % at 41 years (Mannuzza et al. 
[ 17 ]; Klein et al. [ 41 ]). In addition to attrition, these studies used 
different informants and diagnostic criteria classifications at different 
assessment points in adulthood, making it unclear whether the decrease in 
rate was mainly due to age or methodology. Regardless, age at entry into 
the study and age at endpoint clearly affect reported persistence rates. 
 
 
The literature in general also suggests that females might have a higher 
persistence rate than males, as well as more negative outcomes in
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adulthood [ 42 ], although this could not be confirmed in the MTA sample. 
This sex difference might be responsible in part for the lower, in some 
studies absent, male/female preponderance during adulthood (see Matte et 
al. [ 27 ];  Vitola et al., personal communicatio  Please insert here as an "in 
press" reference (it was accepted after our submission). 
 
 
Eduardo Schneider Vitola, MD, MSc1; Claiton Henrique Dotto Bau, MD, PhD1,2; 
Giovanni Abrahão Salum, MD, PhD1,3; Bernardo Lessa Horta, PhD4; Luciana 
Quevedo, PhD4; Fernando Celso Barros, PhD4; Ricardo Tavares Pinheiro, PhD4; 
Christian Kieling, MD, PhD1; Luis Augusto Rohde, MD, PhD1,3; Eugenio Horacio 
Grevet, MD, PhD*1. Exploring DSM-5 ADHD criteria beyond young adulthood: 
phenomenology, psychometric properties and prevalence in a large three-decade 
birth cohort. In press. Pyshcological Medicine.   n). Thus, the proportion of 
females in the study may affect the observed persistence rate. This might 
be even more important in studies reporting persistence rates based on 
samples composed exclusively of males or females [ 17, 20, 21 ]. However, 
these differences might also be due to higher severity, comorbidity, or 
adverse social background of girls diagnosed with ADHD compared to 
boys, instead of being only determined by gender. 
 
 
(d) Informants 
 
 
Who is reporting the information is a major factor explaining 
heterogeneity in worldwide ADHD prevalence in childhood and 
adolescence [ 2 ]. The agreement between parents and teachers on ADHD 
symptoms is low in childhood, and the literature indicates that children 
tend to underreport their ADHD symptoms [ 5 ]. Consequently, the choice 
of the informant in childhood impacts the estimate of prevalence, and 
changing sources may impact estimates of persistence. As a complication, 
this informant effect may differentially influence various aspects of 
ADHD diagnostic criteria (e.g., either symptoms or impairment). 
 
 
Although some reports suggest good inter-rater reliability between adult 
self-report and parent reports of childhood and adulthood symptoms [ 43 ], 
others documented that neither are reliable for retrospectively reporting 
ADHD symptoms in childhood [ 9, •, 44 ]. In adult clinical studies, parents 
or relatives that knew the individual during childhood tend to report 
retrospectively fewer childhood ADHD symptoms than adult retrospective 
self-reports [ 32, 45 ], the opposite of adult current report on symptoms and 
impairments [ 26, •, 42 ].
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Thus, persistence rates will depend heavily on which information source 
was selected during childhood and adulthood. This is especially important 
because some studies change information source from the parent source in 
childhood to affected individual (self) source in adulthood, potentially 
artificially deflating persistence rates [ 9 •, 10 •, 11 •]. 
 
 
 
Data on Persistence Rates From Longitudinal ADHD 
Studies From Childhood to Adulthood 
 
Based on the issues discussed above, it is not surprising that ADHD persistence 
rates from childhood to adulthood vary substantially among studies (Fig. 1 ). The 
figure shows estimates of full ADHD diagnostic persistence reported by 
longitudinal studies that followed children to a mean age of at least 18 years. A 
comparison of the extremes is informative. The lowest rate detected was 4 % in 
a clinical study in the USA [ 17 ]. This study followed referred boys diagnosed 
with DSM-II hyperkinetic disorder at ages 5 to 11 years and reassessed their 
ADHD status 17 years later with DSM-III-R criteria. Potential factors 
responsible for this low rate include the following: (1) The sample was 
composed exclusively of males (see below); (2) patients with comorbid conduct 
disorder at baseline were excluded; (3) change of diagnostic system and 
assessment approach: DSM-II with clinical interview at baseline and DSM-III-R 
with structured interview at follow-up; (4) requirement of endorsement of 
childhood ADHD symptoms and impairment at follow-up to diagnose adult 
ADHD; and (5) the strict use of a DSM threshold instead of a norm-based 
approach. The authors emphasize that recall bias might have constrained the 
persistence rate (see Klein et al. [ 41 ]). The highest ADHD persistence rate 
found was 76 % in the UK study by Cheung and colleagues [ 22 ]. Authors 
followed children and adolescents (mean age 11.8, 87 % males) with ADHD 
combined type (DSM-IV) criteria for 6.6 years. Factors that might be 
responsible for this very high rate include (1) a short follow-up time; (2) 
similarity of assessment in the two time points, using DSM-IV and a structured 
interview and no change of information source (parent report); (3) a clinical 
sample composed of only ADHD combined type (see below); and (4) relatively 
young age at follow-up. 
 
Fig. 1 
 
Estimates of ADHD persistence  rates into adulthood in longitudinal  studies. All 
reported  studies are longitudinal  studies with mean age at follow-up  of at least 
18 years old and a full diagnosis (syndromatic) definition of persistence
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Predictors of ADHD Persistence From Childhood to 
Adulthood 
 
The comprehensive review of persistence rates found few studies that report 
factors in childhood related to the course of symptoms into adulthood. A recent 
systematic review and meta-analysis summarizing the findings thus far 
concluded that available reports are heterogeneous and hard to combine [ 46 ••]. 
However, a meta-analysis of predictors assessed and reported by at least three 
studies is summarized in Table 1 . 
 
Table 1 
 
Summary of risk factors reported in the systematic review and meta-analysis by  Caye and 
colleag  Please  correct citation.  This  table  title  should  cite  reference  46  (Caye  et  al,  2016  in 
ECAP)   ues [ 10 •] 
 
Factors meta-analyzed and significantly associated with persistence 
 
Predictor 
 
Odds 
ratio 
 
95 % Confidence 
interval 
P 
value 
 Severe ADHD 2.33 1.6–3.39 <0.001 
 Treatment for ADHD 2.09 1.04–4.18 0.037 
 
 Comorbid major depressive 
disorder 
 
1.80 
 
1.1–2.95 
 
0.019 
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 Comorbid Conduct Disorder 
 
1.85 
 
1.06–3.24 
 
0.03 
Factors meta-analyzed nonsignificantly associated with persistencea 
 
 
Predictor 
 
Odds 
ratio 
 
95 % Confidence 
interval 
P 
value 
 Female gender 1.23 0.84–1.81 0.295 
 Comorbid ODD 1.65 0.75–3.65 0.213 
Factors meta-analyzed and consistently not associated with persistence 
 
Predictor 
 
Odds 
ratio 
 
95 % Confidence 
interval 
P 
value 
 Single parent family 1.08 0.25–1.29 0.179 
 
Predictor 
 
SMD 
 
95 % Confidence 
interval 
P 
value 
 Intelligence quotient 0.03 −0.18–−0.23 0.8 
Factors not meta-analyzed but associated with persistence in individual studies 
Combined ADHD subtype • comorbid bipolar disorder • parental ASPD 
SMD standardized mean difference, ASPD antisocial personality disorder 
a Authors note that sensitive analysis or the adoption of less conservative meta- 
analysis techniques (fixed-effects models) would result in a positive and significant 
association for comorbid ODD and female gender, whereas single parent family and 
intelligence quotient have consistent small and not significant effects on persistence 
across included studies 
 
 
 
Characteristics of the clinical syndrome were the most consistent risk 
factorfactors for persistence: comorbid Comorbid conditions like conduct 
disorder (CD) and major depressive disorder (MDD), severe ADHD, and 
treatment for ADHD are associated with ADHD persistence. The finding that 
ADHD treatment is a risk factor for persistence is not surprising, since the most 
severe cases are selected for treatment. Barriers to health care may influence this 
finding; lack of access to treatment might be a marker of environmental or 
socioeconomic risk factors (e.g., ethnic minorities or living in an area with 
limited resources [ 47, 48 ]). Importantly, the two studies that found the effect of 
ADHD treatment adjusted their findings for disorder severity, but possibly, the 
treatment-severity relationship was not fully captured by the instruments used. A 
clinical study that followed individuals for 5 years after a 12-month randomized 
clinical trial found that medication adherence was related to greater 
improvement but higher endpoint symptoms, while symptom severity at baseline 
was the most important single predictor of persistent symptoms at follow-up [ 49 
]. Disentangling this bias adequately would require a randomized clinical
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trial with good adherence and retention for several years comparing outcome 
between allocated groups at baseline. However, maintaining adherence to 
assigned treatment over long periods may not be possible. 
 
An analysis of the MTA evaluated childhood factors influencing persistence of 
ADHD into adulthood at a mean age of 24.7 years [ 50 ]. ADHD symptom 
severity, comorbidities, and parental mental health problems were the most 
important risk factors for persistence, while childhood IQ, socioeconomic status, 
parental education, and parent-child relationships showed no association with 
persistence. These findings are, in general, similar to what was reported in the 
meta-analysis (see Table 1 ). However, treatment assignment was not evaluated 
as a risk factor, having been found in previous reports to have lost significant 
association with symptom severity by 3 yearsof follow-up [ 51, 52 ]. 
 
 
Evaluation and Prediction of Trajectories of ADHD 
Symptoms 
 
Another possible approach to evaluate persistence and remission is to investigate 
trajectories of symptoms rather than categorical diagnosis. Since few studies 
using this approach followed subjects from childhood to adulthood, we also 
included studies where the last assessment was in late adolescence in this 
section. 
 
 
One study evaluated baseline differences between trajectories of ADHD 
symptoms (persistently high compared to declining) through grades 3 to 12, 
when participants are expected to be 17 or 18 years old [ 53 ]. Participants with a 
more chronic trajectory were more aggressive and more hyperactive at school 
and more emotionally dysregulated at home than their peers with a declining 
trajectory of ADHD symptoms. The investigators also reported a more stable 
pattern of inattentive symptoms compared to hyperactive symptoms, a finding 
that was reported in previous studies [ 54 ]. In a different study, 8395 twin pairs 
were assessed for ADHD at ages 8, 12, 14, and 16 with a DSM-IV ADHD 
symptom subscale [ 55 ]. Consistent with population-based and clinical studies, 
there was a general decline of symptoms across ages, and inattentive symptoms 
persisted more than hyperactive/impulsive symptoms. Authors reported 
important inter-individual differences in the developmental course of symptoms, 
mostly explained by genetic influences independently of baseline severity. 
Another study  [ 56 ] showed protective effects related to parenting and 
attendance in college that were manifested in the transition from adolescence to 
adulthood  [ 56 ]  Doubled reference in this sentence, please delete the first one (after 
Another study)   . In the adult assessment of the MTA, a dimensional outcome 
based on symptom severity showed a large difference between the overall
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ADHD group and comparison group. However, neither initial random allocation 
to treatment with medication nor self-selected, extended use of medication 
significantly predicted adult outcomes on this variable within the ADHD group 
(Swanson et al., personal communication). 
 
 
The Avon Longitudinal Study of Parents and Children (ALSPAC), a large birth 
cohort in the UK, analyzed factors associated with latent-class trajectories of 
ADHD symptoms age 4 to 17 years. The persistent class (3.9 % of the sample 
and 40.2 % of participants with high childhood scores) had mostly males 
(72.9 %) and higher conduct problems, language impairments, and social 
communication problems and lower IQs. Also, the persistent group had higher 
ADHD genetic liability as indexed by ADHD polygenic risk scores, whereas 
other psychiatric genetic risk scores (schizophrenia, bipolar disorder, and 
depression) were not associated with trajectories (Riglin et al., personal 
communica  Please insert reference here (this paper was accepted and is In press): 
 
 
Authors: Lucy Riglin, Stephan Collishaw, Ajay K. Thapar, Søren Dalsgaard, Kate Langley, 
George Davey Smith, Evie Stergiakouli, Barbara Maughan, Michael C. O’Donovan, Anita 
Thapar. 
 
 
Title: Association of Genetic Risk Variants With Attention-Deficit/Hyperactivity Disorder 
 
Trajectories in the General Population. 
 
 
Journal: JAMA Psychiatry. 
 
 
Year: 2016   tion). 
 
 
Predictors of Adult ADHD Deleterious Outcomes 
That Can Be Detected in Childhood and Adolescence 
 
There is substantial evidence documenting adverse outcomes for those affected 
by ADHD compared to those without the disorder [ 5, 6 ]. ADHD affects a wide 
range of functional domains including academic, social, and occupational 
contexts. Studies have documented lower academic achievement [ 57, 58 ], 
higher unemployment, and lower income for probands with ADHD followed into 
adulthood [ 28, 59, 60 ]. The risk of substance use disorders (SUD) (SUDs) and 
antisocial personality disorder is higher in patients with ADHD than in 
nonaffected individuals [ 61, 62, 63, 64, 65 ]. Individuals with ADHD are more 
likely to have traffic accidents than the general population [ 66, 67, 68 ]. Other 
documented outcomes include obesity [ 69, 70 ], dysfunctional family 
relationships [ 28, 71 ], and emotional dysregulation [ 72 ]. These functional 
impairments may result in reduced perception of well-being [ 73 ] and be related
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to adverse outcomes like higher overall mortality rates in individuals with 
current or past ADHD diagnosis [ 74 ••]. A comprehensive meta-analysis has 
confirmed a longitudinal association of childhood ADHD with adverse 
outcomes, the most relevant being mental disorders and substance abuse, 
academic and professional underachievement, criminality, and risky driving 
behaviors [ 75 ••]. The 16-year follow-up of the MTA showed that adverse 
outcomes in education, work, and risky sexual behavior were associated with 
ADHD and symptom persistence; the risk increases in a progressive fashion: The 
local normative comparison group (LNCG) had the lowest risk, symptom- 
persistent ADHD the highest, with symptom-desistent ADHD in between. For 
emotional outcomes, like anxiety and depression, their difference was not 
significant between those whose symptoms remitted and the LNCG, while both 
were doing better than ADHD persisters. Alcohol use and jail time did not differ 
significantly across any of the groups assessed, probably because alcohol use 
was so common and jail time so rare [ 76 ••]. 
 
 
Although these adverse adult outcomes associated with ADHD are 
unquestionable, much less clear are their childhood predictors. Several factors 
have been suggested as influencing the outcome in ADHD subjects, like the 
clinical profile (ADHD severity and comorbidities), prenatal factors [ 77 ], 
genetic and family loading, gene-environment interactions, and protective 
factors like exercise and cognitive ability [ 5, 78 ]. 
 
 
A recent systematic review and meta-analysis on ADHD and criminality 
consistently identified these risk factors for arrests, convictions, and 
incarcerations [ 79 ]: male sex, low intelligence quotient, severe ADHD, and 
comorbid conduct disorder. Low socioeconomic status was associated in 
univariate analysis, but the effect faded in multivariate analysis. A study of 
unimodal (medication only) and multimodal treatments initiated in the 1970s 
evaluated long-term effects and showed an initial protective effect in the 
multimodal treatment group that dissipated in the adult follow-up [ 80, 81 ]. 
 
 
ADHD severity, comorbid conduct disorder and oppositional defiant disorder, 
sexual abuse, school suspension, family history of SUD or ADHD, and male 
gender were associated with SUD development in ADHD, whereas ADHD 
inattentive subtype and a fearful temperament were inversely associated [ 82 ]. 
One study found that the development of SUD in adulthood was predicted by 
age of treatment initiation in childhood (the later, the higher the risk for SUD) 
and that the relation was moderated by antisocial personality disorder [ 83 ]. The 
MTA found no residual effect of initial assignment to 14-month treatment with 
medication and no effect of current treatment with medication in the 
development of SUD in adolescence [ 84 ]. The PALS, a clinical follow-up,
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found medication to be a risk factor that lost significance when controlling for 
other factors at baseline [ 85 ]. 
 
 
A cross-sectional analysis of data from nationwide registers found the overall 
mortality rate higher among ADHD patients than in the general population, and 
the risk was especially higher in females and with comorbid oppositional defiant 
disorder, conduct disorder, and SUD. The mortality rate ratio was 4.25 (95 % 
confidence interval 3.05–5.78) for individuals diagnosed with ADHD at ages 18 
or older, compared to 1.86 for 5 or younger and 1.58 for those diagnosed 
between 6 and 17 years of age [ 74 ••]. 
 
 
In the Milkauwee follow-up study, higher ADHD scores in childhood predicted a 
wide range of worse outcomes like educational, occupational, financial, and 
driving problems, whereas lower IQ was associated only with worse educational 
and occupational outcomes [ 28 ]. 
 
 
New Adult-Onset Cases and Their Predictors 
Historically, ADHD has been conceptualized as a child-onset 
neurodevelopmental disorder [ 86 ]. The last DSM version (DSM-5) launched in 
2013 [ 1 ] included the disorder in the neurodevelopmental disorder section. 
Three recent population studies from diverse cultures challenged the notion that 
ADHD has its onset only in childhood by suggesting the existence of a 
significant large proportion of individuals who report onset of ADHD symptoms 
and impairments after childhood [ 9 •, 10 •, 11 •]. The most surprising finding 
among the three studies is the similarity in the rates of these new adult-onset 
cases in the three studies: 87 % of the adults with ADHD presented new adult- 
onset in the New Zealand study [ 9 •], 87.4 % in the Brazilian study [ 10 •], and 
67.5 % in the UK investigation [ 11 •]. However, issues have been raised about 
the meaning of these findings. One hypothesis is that the new onset cases are the 
result of the false positive paradox. Another explanation is that in all three 
samples, there was a shift from parent report or teacher report in childhood to 
self-report in adulthood. However, the British study has controlled for this 
potential bias in secondary analyses [ 11 •]. A recent analysis in the ALSPAC 
cohort relying on the same source information for assessments, and using a 
screening instrument for ADHD (hyperactive Strengths and Difficulties 
Questionnaire SDQ scale) at ages 7 and 17 years old (parental assessment), 
found that 54 % of the adult cases were new-onset cases. In addition, the 
persistence rate was only 22 % ( Riglin e  Please insert reference here (this paper 
was accepted and is In press): 
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In an analysis of predictors in childhood for the adult-onset ADHD cases, the 
British study [ 11 •] found that higher IQ and lower externalizing and 
internalizing scores differentiated the adult-onset individuals from the ADHD- 
persistent group. One possible explanation for this would be that high 
intelligence and lack of comorbidity allow the disorder to go undetected during 
childhood and adolescence. In the Dunedin study, the following childhood 
factors differentiate the adult ADHD group from non-ADHD adult group: higher 
ADHD scores by teachers’ report, conduct disorder, and lower reading ability 
scores [ 9 •]. Future investigations need to clarify which factors predict adult- 
onset cases compared to individuals without ADHD. An international effort 
comparing data sets from different cultures on this question is ongoing. 
 
 
Conclusions 
 
Several methodological factors intrinsically related to the ADHD diagnosis (e.g., 
diagnostic criteria), demographic and sample characteristics (e.g., clinical or 
population origin and age), and information source (self or other) seem to be 
responsible for different persistence rates from childhood to adulthood among 
studies. Since evidence from longitudinal studies on ADHD is scarce and 
extremely heterogeneous in methodology, it is difficult to disentangle with 
statistical methods the role of each of these factors in explaining the 
heterogeneity of ADHD persistence rate. This scenario results in a wide range of 
observed persistence rates among studies, from as low as 4 % [ 17 ] to as high as 
76 % [ 22 ]. 
 
 
The available literature indicates that ADHD severity, comorbid conduct 
disorder and major depressive disorder, and treatment for ADHD are the main 
predictors of ADHD persistence from childhood to adulthood [ 46 ••]. Comorbid 
conduct disorder in childhood is ubiquitous as a predictor of multiple adverse 
outcomes like premature mortality, SUD, and criminality, whereas other factors 
have controversial effects depending on the study. Male sex is a risk factor for 
SUD and criminality but is protective in terms of the overall mortality rate.
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Stimulant medication use may protect against the development of SUD (although 
the MTA, the largest prospective study, failed to find such an effect). Severity of 
ADHD appears to be positively associated with criminality and SUD, but its 
relationship with mortality could not be assessed due to lack of data. 
 
 
Finally, innovative investigations like those suggesting the possibility of an 
adult-onset ADHD trajectory predicted by higher cognitive reserve and lower 
symptomatology in childhood are important to expand our knowledge about 
ADHD trajectories across the life cycle. 
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